SCLX Scilex Holding
- 0.818
- +0.018+2.29%
- 0.840
- +0.022+2.65%
Scilex Holding News
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
Positive Sentiment Still Eludes Scilex Holding Company (NASDAQ:SCLX) Following 39% Share Price Slump
To the annoyance of some shareholders, Scilex Holding Company (NASDAQ:SCLX) shares are down a considerable 39% in the last month, which continues a horrid run for the company.
10-Q: Quarterly report
Scilex Provides Information To Stockholders Regarding Manipulative And Naked Short Selling Of Its Common Stock
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. : The Scilex Holding (SCLX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $8.00.
HC Wainwright & Co. : The Scilex Holding (SCLX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $12.00 to $8.00.
HC Wainwright & Co. Maintains Buy on Scilex Holding, Lowers Price Target to $8
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Scilex Holding (NASDAQ:SCLX) with a Buy and lowers the price target from $12 to $8.
Scilex Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 831.15% HC Wainwright & Co. $12 → $8 Maintains Buy 12/04/2023 1296.73% HC Wainwright & Co. → $1
Scilex Falls on Direct Offering to Raise $15M
Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share
Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share
Scilex Issues Preliminary Q1 Sales Results for ZTlido
Scilex Holding (SCLX) said Tuesday that Q1 net sales of ZTlido are expected to be between $12 million and $13 million, compared with $10.6 million in Q1 2023. The company also said that it plans to re
Scilex to Reduce R&D Expenses in 2024, Comments on Actions Post Change Healthcare Cyberattack
Scilex Holding Preliminary Q1 Net Sales For ZTlido Were $12M-$13M; Q1 Gross Sales For ZTlido Were $34M-$38M; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the Addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Scilex Holding Company (Nasdaq: SCLX）today announced launching of co-pay programs for both ZTlido and ELYXYB with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0.
Scilex Holding Says U.S. Bankruptcy Court Extended Lockup Period on Shares Previously Distributed by Sorrento to Its Stockholders as a Dividend >SCLX
Scilex Holding Says U.S. Bankruptcy Court Extended Lockup Period on Shares Previously Distributed by Sorrento to Its Stockholders as a Dividend >SCLX
Scilex Holding Ends Equity Purchase Deal With Yorkville
Scilex Holding Co And Ya II PN Mutually Agreed To Terminate Amended And Restated Standby Equity Purchase Agreement, Dated As Of Feb 8, 2023
Scilex Holding Co And Ya II PN Mutually Agreed To Terminate Amended And Restated Standby Equity Purchase Agreement, Dated As Of Feb 8, 2023
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
Scilex has been working with its co-pay savings card adjudicators to resolve the recent breakdown of processing of insurance claims by Change Healthcare, following a cyber-attack on Change Healthcare.
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label
Scilex Holding (SCLX) said Wednesday it plans to seek approval from the US Food and Drug Administration to change the label of gout drug Gloperba to add dosing guidance for people with renal impairmen
Analysis
Price Target
No Data
